A Phase II, randomised, placebo-controlled, double-blind, parallel-group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with early progressive diffuse cutaneous systemic sclerosis

Clinical Studies - May 22, 2023 - May 22, 2026

Ongoing

Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana

A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACE-1334 Plus Standard of Care in Participants with Systemic Sclerosis

Clinical Studies - Apr 14, 2023 - Apr 14, 2026

Ongoing

Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana

A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase3 trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo,in combination with a glucocorticoid taper regimen, in patients with po...

Clinical Studies - Mar 10, 2023 - Mar 10, 2026

Ongoing

Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana

A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper...

Clinical Studies - Jan 1, 2022 - Jan 1, 2025

Ongoing

Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana